prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |review
Fluvastatin and bezafibrate, alone and in combination, were evaluated for their effects on fibrinogen, plasminogen activator inhibitor 1 (PAI-1), and CRP in 333 patients with hyperlipidemia (LDL-C 135250 mg/dL, triglyceride 180400 mg/dL) and stable angina, prior myocardial infarction, or coronary revascularization. Patients were randomized to receive fluvastatin 40 mg (not shown), bezafibrate 400 mg, bezafibrate 400 mg + fluvastatin 20 mg, or bezafibrate 400 mg + fluvastatin 40 mg for 24 weeks. Plasma fibrinogen was significantly decreased by 9%, 14%, and 16% in the respective bezafibrate treatment groups. PAI-1 and CRP levels did not change with any of the treatment regimens. 

Reference:
Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R, on behalf of the FACT study centers. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Thromb Haemost 2000;83:549-553.
Web site